A meta-analysis of chemokines in vitiligo: Recruiting immune cells towards melanocytes

Speeckaert, Reinhart; Belpaire, Arno; Speeckaert, Marijn M.; Geel, Nanja van

doi:10.3389/fimmu.2023.1112811

“…Elevated values of CXCL4 have not been confirmed by other studies in vitiligo. Nonetheless, increased CXCL4 levels would be consistent with an upregulated CXCR3 signaling in vitiligo ( 19 ). CXCL7 is also released from activated platelets and orchestrates neutrophil recruitment.…”

Section: Resultsmentioning

confidence: 87%

Proteomics data in vitiligo: a scoping review

Berrevoet,

Van Nieuwerburgh,

Deforce

et al. 2024

Front. Immunol.

Self Cite

0

View full text Add to dashboard Cite

An unbiased screening of which proteins are deregulated in vitiligo using proteomics can offer an enormous value. It could not only reveal robust biomarkers for detecting disease activity but can also identify which patients are most likely to respond to treatments. We performed a scoping review searching for all articles using proteomics in vitiligo. Eight manuscripts could be identified. Unfortunately, very limited overlap was found in the differentially expressed proteins between studies (15 out of 272; 5,51%) with variable degrees of the type of proteins and a substantial variety in the prevalence of acute phase proteins (range: 6-65%). Proteomics research has therefore brought little corroborating evidence on which proteins are differentially regulated between vitiligo patients and healthy controls or between active and stable vitiligo patients. While a limited patient size is an obvious weakness for several studies, an incomplete description of patient characteristics is an unfortunate and avoidable shortcoming. Additionally, the variations in the used methodology and analyses may further contribute to the overall observed variability. Nonetheless, more recent studies investigating the response to treatment seem to be more robust, as more differentially expressed proteins that have previously been confirmed to be involved in vitiligo were found. The further inclusion of proteomics analyses in clinical trials is recommended to increase insights into the pathogenic mechanisms in vitiligo and identify reliable biomarkers or promising drug targets. A harmonization in the study design, reporting and proteomics methodology could vastly improve the value of vitiligo proteomics research.

show abstract

“…Because Th1-dominant immunity in idiopathic VKH syndrome ( 6 ) and vitiligo vulgaris ( 13 ) is common and well-known, the Th2 reaction in the current case is unusual. Considering that prodromal erythema is rare in vaccine-related vitiligo ( 11 ) and idiopathic VKH syndrome ( 12 ), atypical Th2 immunity would contribute to the characteristic prodromal erythema in the current case.…”

Section: Discussionmentioning

confidence: 83%

Vogt-Koyanagi-Harada Syndrome Following COVID-19 mRNA Vaccination: Th2 to Th1 Transition-related Molecular Machinery

Ikuno,

Yamaguchi,

Takahashi

et al. 2024

Acta Derm Venereol

1

0

View full text Add to dashboard Cite

show abstract

“…Elevated values of CXCL4 have not been confirmed by other studies in vitiligo. Nonetheless, increased CXCL4 levels would be consistent with an upregulated CXCR3 signaling in vitiligo (16). CXCL7 is also released from activated platelets and orchestrates neutrophil recruitment.…”

mentioning

confidence: 69%

“…Nonetheless, increased CXCL4 levels would be consistent with an upregulated CXCR3 signaling in vitiligo. (16) CXCL7 is also released from activated platelets and orchestrates neutrophil recruitment. Vitiligo is however not a neutrophilic disorder leaving the possible implication of CXCL7 largely unexplained.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Proteomics data in vitiligo: a scoping review

Berrevoet,

Van Nieuwerburgh,

Deforce

et al. 2024

Preprint

Self Cite

0

View full text Add to dashboard Cite

An unbiased screening of which proteins are deregulated in vitiligo using proteomics can offer an enormous value. It could not only reveal robust biomarkers for detecting disease activity but can also identify which patients are most likely to respond to treatments. We performed a scoping review searching for all articles using proteomics in vitiligo. Eight manuscripts could be identified. Unfortunately, very limited overlap was found in the differentially expressed proteins between studies (15 out of 272; 5,51%) with variable degrees of the type of proteins and a substantial variety in the prevalence of acute phase proteins (range: 6-65%). Proteomics research has therefore brought little corroborating evidence on which proteins are differentially regulated between vitiligo patients and healthy controls or between active and stable vitiligo patients. While a limited patient size is an obvious weakness for several studies, an incomplete description of patient characteristics is an unfortunate and avoidable shortcoming. Additionally, the variations in the used methodology and analyses may further contribute to the overall observed variability. Nonetheless, more recent studies investigating the response to treatment seem to be more robust, as more differentially expressed proteins that have previously been confirmed to be involved in vitiligo were found. The further inclusion of proteomics analyses in clinical trials is recommended to increase insights into the pathogenic mechanisms in vitiligo and identify reliable biomarkers or promising drug targets. A harmonization in the study design, reporting and proteomics methodology could vastly improve the value of vitiligo proteomics research.

show abstract

A meta-analysis of chemokines in vitiligo: Recruiting immune cells towards melanocytes

Cited by 14 publications

References 51 publications

Proteomics data in vitiligo: a scoping review

Proteomics data in vitiligo: a scoping review

Vogt-Koyanagi-Harada Syndrome Following COVID-19 mRNA Vaccination: Th2 to Th1 Transition-related Molecular Machinery

Proteomics data in vitiligo: a scoping review

Contact Info

Product

Resources

About